{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:55:50Z","timestamp":1760244950284,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.humpath.2012.02.003","type":"journal-article","created":{"date-parts":[[2012,5,9]],"date-time":"2012-05-09T11:24:15Z","timestamp":1336562655000},"page":"1948-1954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"43","author":[{"given":"Dariusz","family":"Borys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Canter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve R.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Tamurian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Horvai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2012.02.003_bb0005","doi-asserted-by":"crossref","first-page":"8845","DOI":"10.1200\/JCO.2004.00.5785","article-title":"Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups","volume":"23","author":"Ferrari","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1179\/joc.2002.14.2.198","article-title":"High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group\/Scandinavian Sarcoma Group pilot study","volume":"14","author":"Bacci","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.humpath.2012.02.003_bb0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-4615-3518-8_36","article-title":"Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities: the recent experience at the Rizzoli Institute","volume":"62","author":"Bacci","year":"1993","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.humpath.2012.02.003_bb0020","first-page":"705","article-title":"Osteosarcoma: a review of diagnosis, management, and treatment strategies","volume":"8","author":"Geller","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1179\/joc.2001.13.1.93","article-title":"Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR\/OS-3b protocol","volume":"13","author":"Bacci","year":"2001","journal-title":"J Chemother"},{"key":"10.1016\/j.humpath.2012.02.003_bb0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00003086-200105000-00024","article-title":"Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy","author":"Bacci","year":"2001","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.humpath.2012.02.003_bb0035","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.ejca.2005.03.036","article-title":"Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution","volume":"41","author":"Bacci","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2012.02.003_bb0040","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/cncr.11456","article-title":"Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor","volume":"97","author":"Bacci","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2012.02.003_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.1997.15.1.76","article-title":"Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group","volume":"15","author":"Provisor","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0050","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0959-8049(02)00747-5","article-title":"Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders","volume":"39","author":"Smeland","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2012.02.003_bb0055","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.1998.16.7.2452","article-title":"Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol","volume":"16","author":"Meyers","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0060","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/pbc.20314","article-title":"Methotrexate levels and outcome in osteosarcoma","volume":"44","author":"Zelcer","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.humpath.2012.02.003_bb0065","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/00043426-200311000-00006","article-title":"Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome","volume":"25","author":"Bacci","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0070","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrc2696","article-title":"Emerging roles of E2Fs in cancer: an exit from cell cycle control","volume":"9","author":"Chen","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2012.02.003_bb0075","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2174\/138945009788680392","article-title":"The rb pathway and cancer therapeutics","volume":"10","author":"Du","year":"2009","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.humpath.2012.02.003_bb0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D","article-title":"Alteration of pRb\/p16\/cdk4 regulation in human osteosarcoma","volume":"84","author":"Benassi","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2012.02.003_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/1097-0215(20010120)95:1<34::AID-IJC1006>3.0.CO;2-V","article-title":"Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas","volume":"95","author":"Maitra","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2012.02.003_bb0090","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/gcc.20817","article-title":"Small deletions but not methylation underlie CDKN2A\/p16 loss of expression in conventional osteosarcoma","volume":"49","author":"Mohseny","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"14 Pt","key":"10.1016\/j.humpath.2012.02.003_bb0095","first-page":"123","article-title":"Clinicopathologic spectrum of osteogenic sarcoma. Recent observations","volume":"1","author":"Huvos","year":"1979","journal-title":"Pathol Annu"},{"key":"10.1016\/j.humpath.2012.02.003_bb0100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/BF01655660","article-title":"Surgical pathology of bone sarcomas","volume":"12","author":"Huvos","year":"1988","journal-title":"World J Surg"},{"key":"10.1016\/j.humpath.2012.02.003_bb0105","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1023\/A:1011636912674","article-title":"Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute","volume":"12","author":"Ferrari","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0110","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/030089169908500607","article-title":"Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR\/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response","volume":"85","author":"Ferrari","year":"1999","journal-title":"Tumori"},{"key":"10.1016\/j.humpath.2012.02.003_bb0115","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199511233332103","article-title":"Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome","volume":"333","author":"Baldini","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2012.02.003_bb0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jor.1100170502","article-title":"P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy","volume":"17","author":"Baldini","year":"1999","journal-title":"J Orthop Res"},{"key":"10.1016\/j.humpath.2012.02.003_bb0125","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2003.03.144","article-title":"Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities","volume":"21","author":"Serra","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0130","first-page":"3065","article-title":"Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma","volume":"7","author":"Gorlick","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2012.02.003_bb0135","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.1999.17.9.2781","article-title":"Expression of HER2\/erbB-2 correlates with survival in osteosarcoma","volume":"17","author":"Gorlick","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10024-005-0044-5","article-title":"HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study","volume":"8","author":"Somers","year":"2005","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0145","first-page":"210","article-title":"Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma","volume":"25","author":"Hernandez-Rodriguez","year":"2001","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.humpath.2012.02.003_bb0150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/13577149778245","article-title":"A randomized comparison of two short intensive chemotherapy regimens in children and young adults with osteosarcoma: results in patients with metastases: a study of the European Osteosarcoma Intergroup","volume":"1","author":"Bramwell","year":"1997","journal-title":"Sarcoma"},{"key":"10.1016\/j.humpath.2012.02.003_bb0155","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(97)02307-6","article-title":"Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup","volume":"350","author":"Souhami","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2012.02.003_bb0160","first-page":"1117","article-title":"Expression of G1 phase regulators in MG-63 osteosarcoma cell line","volume":"14","author":"Merli","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0165","first-page":"1007","article-title":"Prognostic significance of cyclin expression in human osteosarcoma","volume":"12","author":"Molendini","year":"1998","journal-title":"Int J Oncol"},{"key":"10.1016\/j.humpath.2012.02.003_bb0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-4608(99)00255-1","article-title":"Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma","volume":"120","author":"Tsuchiya","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.humpath.2012.02.003_bb0175","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X","article-title":"Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma","volume":"92","author":"Benassi","year":"2001","journal-title":"Cancer"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817712000469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817712000469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:34:51Z","timestamp":1758645291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817712000469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0046817712000469"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2012.02.003","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2012.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}